Test diretto all’antiglobulina stimolato con mitogeni

Translated title of the contribution: Mitogen-stimulated DAT: A new method for the diagnosis of AIHA

Wilma Barcellini, Anna Zaninoni, Francesca Guia Imperiali, Alberto Zanella

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background. Direct antiglobulin test (DAT), the hallmark of autoimmune haemolytic anaemia (AIHA), can be performed with different laboratory techniques, which have variable sensitivity and/or specificity. In a minority of patients, named DAT-negative AIHA, the diagnosis is made in exclusion. We recently described a new method for the detection of anti-RBC antibodies in mitogen-stimulated whole blood cultures, named mitogen-stimulated-DAT (MS-DAT). Aim. To investigate the prevalence of MS-DAT positivity in a larger series of DAT-positive and DAT-negative AIHA at different states of disease activity, and in B-CLL with or without DAT-positive AIHA. Materials and methods. We studied 33 DAT-positive AIHA with different disease activity, 7 DAT-negative AIHA, and 69 B-CLL patients. MS-DAT was performed by stimulating whole blood cultures with mitogens, and anti-RBC antibodies were detected by competitive solid phase ELISA. Standard DAT was performed with tube test, in solid phase and with enhancing solutions. Results. MS-DAT was positive in 6 DAT-negative patients with a history of DAT-positive AIHA, who were in clinical and laboratory remission at the moment of the study, and in 7 DAT-negative haemolytic anaemias, diagnosed as autoimmune in exclusion. MS-DAT was positive in 1/3 of the B-CLL patients without haemolytic features. MS-DAT was routinely performed during the follow-up of AIHA patients, and its values correlated with the clinical course, haemolytic parameters and response to therapy. Conclusions. In the test described here mitogen stimulation seems able to disclose a latent anti-RBC autoimmunity, both in AIHA in clinical remission and in B-CLL. MS-DAT could be proposed as an additional test for the diagnosis and monitoring of AIHA, and for the screening of those pathological conditions in which anti-RBC autoimmunity is known to be potentially harmful.

Original languageItalian
Pages (from-to)127-136
Number of pages10
JournalBlood Transfusion
Volume1
Issue number2
Publication statusPublished - 2003

Fingerprint

Coombs Test
Autoimmune Hemolytic Anemia
Mitogens
Autoimmunity
Anti-Idiotypic Antibodies
Hemolytic Anemia

ASJC Scopus subject areas

  • Hematology
  • Immunology and Allergy

Cite this

Test diretto all’antiglobulina stimolato con mitogeni. / Barcellini, Wilma; Zaninoni, Anna; Imperiali, Francesca Guia; Zanella, Alberto.

In: Blood Transfusion, Vol. 1, No. 2, 2003, p. 127-136.

Research output: Contribution to journalArticle

Barcellini, Wilma ; Zaninoni, Anna ; Imperiali, Francesca Guia ; Zanella, Alberto. / Test diretto all’antiglobulina stimolato con mitogeni. In: Blood Transfusion. 2003 ; Vol. 1, No. 2. pp. 127-136.
@article{dfffd807658a43058dd048bda0d59c0a,
title = "Test diretto all{\^a}€™antiglobulina stimolato con mitogeni",
abstract = "Background. Direct antiglobulin test (DAT), the hallmark of autoimmune haemolytic anaemia (AIHA), can be performed with different laboratory techniques, which have variable sensitivity and/or specificity. In a minority of patients, named DAT-negative AIHA, the diagnosis is made in exclusion. We recently described a new method for the detection of anti-RBC antibodies in mitogen-stimulated whole blood cultures, named mitogen-stimulated-DAT (MS-DAT). Aim. To investigate the prevalence of MS-DAT positivity in a larger series of DAT-positive and DAT-negative AIHA at different states of disease activity, and in B-CLL with or without DAT-positive AIHA. Materials and methods. We studied 33 DAT-positive AIHA with different disease activity, 7 DAT-negative AIHA, and 69 B-CLL patients. MS-DAT was performed by stimulating whole blood cultures with mitogens, and anti-RBC antibodies were detected by competitive solid phase ELISA. Standard DAT was performed with tube test, in solid phase and with enhancing solutions. Results. MS-DAT was positive in 6 DAT-negative patients with a history of DAT-positive AIHA, who were in clinical and laboratory remission at the moment of the study, and in 7 DAT-negative haemolytic anaemias, diagnosed as autoimmune in exclusion. MS-DAT was positive in 1/3 of the B-CLL patients without haemolytic features. MS-DAT was routinely performed during the follow-up of AIHA patients, and its values correlated with the clinical course, haemolytic parameters and response to therapy. Conclusions. In the test described here mitogen stimulation seems able to disclose a latent anti-RBC autoimmunity, both in AIHA in clinical remission and in B-CLL. MS-DAT could be proposed as an additional test for the diagnosis and monitoring of AIHA, and for the screening of those pathological conditions in which anti-RBC autoimmunity is known to be potentially harmful.",
keywords = "AIHA, Autoimmunity, B-CLL, Mitogen-stimulated DAT",
author = "Wilma Barcellini and Anna Zaninoni and Imperiali, {Francesca Guia} and Alberto Zanella",
year = "2003",
language = "Italian",
volume = "1",
pages = "127--136",
journal = "Blood Transfusion",
issn = "1723-2007",
publisher = "Edizioni SIMTI",
number = "2",

}

TY - JOUR

T1 - Test diretto all’antiglobulina stimolato con mitogeni

AU - Barcellini, Wilma

AU - Zaninoni, Anna

AU - Imperiali, Francesca Guia

AU - Zanella, Alberto

PY - 2003

Y1 - 2003

N2 - Background. Direct antiglobulin test (DAT), the hallmark of autoimmune haemolytic anaemia (AIHA), can be performed with different laboratory techniques, which have variable sensitivity and/or specificity. In a minority of patients, named DAT-negative AIHA, the diagnosis is made in exclusion. We recently described a new method for the detection of anti-RBC antibodies in mitogen-stimulated whole blood cultures, named mitogen-stimulated-DAT (MS-DAT). Aim. To investigate the prevalence of MS-DAT positivity in a larger series of DAT-positive and DAT-negative AIHA at different states of disease activity, and in B-CLL with or without DAT-positive AIHA. Materials and methods. We studied 33 DAT-positive AIHA with different disease activity, 7 DAT-negative AIHA, and 69 B-CLL patients. MS-DAT was performed by stimulating whole blood cultures with mitogens, and anti-RBC antibodies were detected by competitive solid phase ELISA. Standard DAT was performed with tube test, in solid phase and with enhancing solutions. Results. MS-DAT was positive in 6 DAT-negative patients with a history of DAT-positive AIHA, who were in clinical and laboratory remission at the moment of the study, and in 7 DAT-negative haemolytic anaemias, diagnosed as autoimmune in exclusion. MS-DAT was positive in 1/3 of the B-CLL patients without haemolytic features. MS-DAT was routinely performed during the follow-up of AIHA patients, and its values correlated with the clinical course, haemolytic parameters and response to therapy. Conclusions. In the test described here mitogen stimulation seems able to disclose a latent anti-RBC autoimmunity, both in AIHA in clinical remission and in B-CLL. MS-DAT could be proposed as an additional test for the diagnosis and monitoring of AIHA, and for the screening of those pathological conditions in which anti-RBC autoimmunity is known to be potentially harmful.

AB - Background. Direct antiglobulin test (DAT), the hallmark of autoimmune haemolytic anaemia (AIHA), can be performed with different laboratory techniques, which have variable sensitivity and/or specificity. In a minority of patients, named DAT-negative AIHA, the diagnosis is made in exclusion. We recently described a new method for the detection of anti-RBC antibodies in mitogen-stimulated whole blood cultures, named mitogen-stimulated-DAT (MS-DAT). Aim. To investigate the prevalence of MS-DAT positivity in a larger series of DAT-positive and DAT-negative AIHA at different states of disease activity, and in B-CLL with or without DAT-positive AIHA. Materials and methods. We studied 33 DAT-positive AIHA with different disease activity, 7 DAT-negative AIHA, and 69 B-CLL patients. MS-DAT was performed by stimulating whole blood cultures with mitogens, and anti-RBC antibodies were detected by competitive solid phase ELISA. Standard DAT was performed with tube test, in solid phase and with enhancing solutions. Results. MS-DAT was positive in 6 DAT-negative patients with a history of DAT-positive AIHA, who were in clinical and laboratory remission at the moment of the study, and in 7 DAT-negative haemolytic anaemias, diagnosed as autoimmune in exclusion. MS-DAT was positive in 1/3 of the B-CLL patients without haemolytic features. MS-DAT was routinely performed during the follow-up of AIHA patients, and its values correlated with the clinical course, haemolytic parameters and response to therapy. Conclusions. In the test described here mitogen stimulation seems able to disclose a latent anti-RBC autoimmunity, both in AIHA in clinical remission and in B-CLL. MS-DAT could be proposed as an additional test for the diagnosis and monitoring of AIHA, and for the screening of those pathological conditions in which anti-RBC autoimmunity is known to be potentially harmful.

KW - AIHA

KW - Autoimmunity

KW - B-CLL

KW - Mitogen-stimulated DAT

UR - http://www.scopus.com/inward/record.url?scp=47749092067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47749092067&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:47749092067

VL - 1

SP - 127

EP - 136

JO - Blood Transfusion

JF - Blood Transfusion

SN - 1723-2007

IS - 2

ER -